Responding to declining artemether lumefantrine efficacy in African malaria programs
Recent U.S. CDC guidance extended artemether–lumefantrine (AL) treatment for uncomplicated malaria from 3 to 5 days, raising questions about its relevance to African programs. This recommendation, developed for U.S. clinical practice, does not by itself justify changing African national guidelines. Although artemisinin partial resistance and reduced AL efficacy have been reported at selected African sites, these findings do not establish that standard AL is ineffective across the continent. African trials comparing 3- and 5-day regimens have reported greater lumefantrine exposure with extended treatment, but increased exposure alone does not demonstrate better cure rates, reduced recrudescence or feasibility in routine care. This perspective argues for geographically targeted evaluation rather than blanket adoption. Such studies should integrate therapeutic efficacy outcomes with molecular resistance surveillance, pharmacokinetic data, medicine-quality verification, and assessments of adherence and implementation. Comparative studies should establish whether extended AL offers meaningful clinical advantages over standard AL or alternative effective ACTs before treatment-policy changes are considered.
Authors
- Faith Adedayo Adejumo (ORCID: https://orcid.org/0009-0005-3616-5012)
- Ayomide Raphael Ijabadeniyi
Institutions
- Bowen University (NG)
Publication Details
- Journal
- Discover Public Health
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1186/s12982-026-03259-1
- Primary Topic
- Malaria Research and Control
- Type
- article
- Field-Weighted Citation Impact
- 0.00